Results 81 to 90 of about 2,223,665 (257)

Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis

Journal of Experimental & Clinical Cancer Research, 2020
Background The identification of novel targets for recovering sorafenib resistance is pivotal for Hepatocellular carcinoma (HCC) patients. Mitophagy is the programmed degradation of mitochondria, and is likely involved in drug resistance of cancer cells.
Hong Wu, Tao Wang, Yiqiang Liu, Xin Li, Senlin Xu, Changtao Wu, Hongbo Zou, Mianfu Cao, Guoxiang Jin, Jinyi Lang, Bin Wang, Baohua Liu, Xiaolin Luo, Chuan Xu   +13 more
doaj   +1 more source

Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma

World Journal of Hepatology, 2013
Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma (HCC), has opened a window of hope after searching for effective agents to combat HCC for decades. However, the overall outcomes are far from satisfactory. One of the explanations is the genetic heterogeneity of HCC, which has led to identifying predictive ...
Bo, Zhai, Xue-Ying, Sun
openaire   +2 more sources

RBM38 Reverses Sorafenib Resistance in Hepatocellular Carcinoma Cells by Combining and Promoting lncRNA-GAS5

, 2023
Background: Hepatocellular carcinoma (HCC) is a life-threatening human malignancy and the fourth leading cause of cancer-related deaths worldwide. Patients with HCC are often diagnosed at an advanced stage with a poor prognosis.
Julu Huang, Xi Huang, Rong Liang, Lu Lu, Minchao Tang, Ziyu Liu, Ziqin He, Jiazhou Ye, Yan Lin, Xing Gao, Shilin Huang, Xiaomin She, Cheng Lu, Shuanghang Li   +13 more
core   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma

Frontiers in Oncology, 2023
Hepatocellular carcinoma (HCC) is a heterogeneous and aggressive liver cancer that presents limited treatment options. Despite being the standard therapy for advanced HCC, sorafenib frequently encounters resistance, emphasizing the need to uncover the ...
Siqi Chen, Siqi Chen, Siqi Chen, Yaqing Du, Xin-Yuan Guan, Qian Yan, Qian Yan, Qian Yan   +7 more
doaj   +1 more source

Toward Predictable Nanomedicine: Current Forecasting Frameworks for Nanoparticle–Biology Interactions

Advanced Intelligent Discovery, EarlyView.
Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova, Michael Nicholls, Nicola Russo, Gueorgui Mihaylov, Konstantin Nikolic   +4 more
wiley   +1 more source

Incapacitated Capicua in Sorafenib-Resistant HCC [PDF]

Cellular and Molecular Gastroenterology and Hepatology, 2020
Dingzi Yin, PhD, Kirk J. Wangensteen, MD, PhD   +1 more
openaire   +3 more sources

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib [PDF]

Journal of Experimental & Clinical Cancer Research, 2017
Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast growth factor 19 (FGF19) expression correlates with tumor ...
Gao, Lixia, Wang, Xuli, Tang, Yaoliang, Huang, Shuang, Hu, Chien-An Andy, Teng, Yong   +5 more
openaire   +2 more sources

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study

American Journal of Hematology, EarlyView.
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, Pilar Lloret‐Madrid, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa del Bernal del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, Joaquín Sánchez‐García, Carlos Rodríguez‐Medina, José Mário Mariz, Rosa Ayala, Joaquín Martínez‐López, María Luz Amigo, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Tamara Castaño, Juan M. Bergua Burgués, Olga Salamero, María Francisca Bass Maturana, Mercedes Colorado, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Carmen Chillón, Esther Pérez Santaolalla, María Dolores Madrigal, Jorge Labrador Gómez, María José García Pérez, Soledad Casado Calderón, Manuel Pérez Encinas, Amaia Balerdi Malcorra, María Solé Rodríguez, Lara María Gómez García, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Víctor Noriega, Rosa Fernández, Mamen Mateos, Carolina Lacalzada, Ágata Almela Gallego, María Carmen García Garay, Carmen Couto, José Antonio Pérez‐Simón, Eva Barragán González, Pau Montesinos   +49 more
wiley   +1 more source

Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib [PDF]

Clinical Cancer Research, 2012
Abstract Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials.
Augusto, Villanueva, Josep M, Llovet
openaire   +2 more sources